Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market definitions
1.3 Base estimates and calculations
1.4 Forecast calculations
1.5 Data sources
1.6 Data validation
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Lung Cancer Treatment industry 360° synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Type trends
2.1.3 By Therapy trends
2.1.4 End-user trends
2.1.5 Regional trends
Chapter 3 Lung Cancer Treatment Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of lung cancer across the globe
3.2.1.2 The growing trend of smoking tobacco
3.2.1.3 Rising levels of air pollution due to rapid industrialization
3.2.1.4 Increasing emphasis on early diagnosis of cancers
3.2.1.5 Rising technological advancements in lung cancer treatment
3.2.1.6 Availability of reimbursement for lung cancer treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 The high cost of lung cancer treatments
3.2.2.2 Side effects of drugs and therapies
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By therapy
3.3.3 By end-user
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Technology landscape
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Competitive dashboard, 2022
4.3 Company matrix analysis, 2022
4.4 Company market share analysis, 2022
4.5 Competitive positioning matrix, 2022
4.6 Strategic outlook matrix, 2022
Chapter 5 Lung Cancer Treatment Market Estimates and Forecast, By Type (USD Million)
5.1 Key trends, by type
5.2 Non-small cell lung cancer
5.3 Small cell lung cancer
5.4 Carcinoid
Chapter 6 Lung Cancer Treatment Market Estimates and Forecast, By Therapy (USD Million)
6.1 Key trends, by therapy
6.2 Radiation therapy
6.3 Immunotherapy
6.4 Targeted therapy
6.5 Chemotherapy
6.6 Other therapies
Chapter 7 Lung Cancer Treatment Market Estimates and Forecast, By End-user (USD Million)
7.1 Key trends, by end-user
7.2 Hospitals
7.3 Specialty clinics
7.4 Homecare
7.5 Other end-users
Chapter 8 Lung Cancer Treatment Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Merck KGaA
9.2 ONO PHARMACEUTICAL CO., LTD.
9.3 Boehringer Ingelheim International GmbH
9.4 GlaxoSmithKline plc.
9.5 Pfizer Inc.
9.6 Johnson & Johnson Services, Inc.
9.7 AstraZeneca
9.8 Takeda Pharmaceutical Company Limited
9.9 Church & Dwight Co., Inc.
9.10 Sun Pharmaceutical Industries Ltd.Takara Bio Inc.
